Targeting gangliosides to treat Alzheimer’s and Parkinson’s diseases: A disruptive approach with the first-in-class peptide AmyP53

Neural Regen Res. 2026 Jun 1;21(6):2339-2340

Poster AmyP53 3D F3

J. Fantini, N. Yahi - Neural Regeneration Research 2026

DOI: 10.4103/NRR.NRR-D-25-00076

Perspective article in which Jacques Fantini and Nouara Yahi present the targeting of brain gangliosides as a disruptive therapeutic approach for Alzheimer’s and Parkinson’s diseases, with the first-in-class adaptive peptide AmyP53.

Retour